Cerebrolysin after Thrombolysis: Is the Positive Trend Sustainable? Moskovko S., Vysochanska T., Bartiuk R., Vysochanskiy O., Kostenko T., Karpenko N., Korobchuk N., Matiyuk S., Sinitska I., Smotritska T., Fix D., Soroka N., Moskovko G. Aim: To compare the clinical benefit of early (≤1 h) and late (22-24 h) initiation of Cerebrolysin treatment in thrombolysed stroke patients. Methods: In this retrospective study Cerebrolysin was administered either one (n=47) or 22-24 (n=60) hours after thrombolysis; both groups were compared to a control group treated with rt-PA only (n=220). The dosage regimen for Cerebrolysin was 30 mL daily for 5 days followed by 20 mL daily for two to ten consecutive days. Concomitant early mobilization and rehabilitation therapy was performed in all patients. Efficacy was assessed by mRS at day 90. Results : The percentage of patients with an mRS score 0 - 2 at day 90 was 66% in the Cerebrolysin group with early initiation, 60% in the Cerebrolysin group with late initiation, and 50% in the control group (rt-PA only). In comparison to controls, a significant advantage was reported for patients treated with Cerebrolysin within one hour after thrombolysis. In line, the mortality rate was also lowest in those thrombolyzed patients starting treatment with Cerebrolysin within one hour (4.3%) vs. 22-24 hours (7.7%) vs. rt-PA only (10.5%). Conclusion: This study showed a clear clinical advantage of starting Cerebrolysin treatment within one hour after thrombolysis. Furthermore, this therapy was safe and well tolerated. These results should be confirmed in larger randomized, controlled studies.
No datasets are available for this submission.
No license information is available for this submission.